glp-1 cardiovascular outcomes 2025 news The effects of receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action GLP-1 Drugs: 2025 Pulse Survey

CSD acts by mimicking the inhibitory effect of full-length CAV-1 on signaling 7

S.ViardotA.PsichasA.MorrisonD

Semaglutide (Wegovy) has been granted FDA approval for the treatment of metabolic-associated steatohepatitis (MASH, or NASH with fibrosis)

Akkermansia+: 1 serving for daily microbiome support

Alex Fishman, brand director at Pure Protein, added: As the dietary supplement market in the US becomes increasingly more congested and expensive, users and especially those taking GLP-1 medications are seeking simplified, yet effective solutions to help them achieve their health and fitness goals

The CV effect of oral semaglutide for patients with T2D and ASCVD and/or chronic kidney disease (CKD) was investigated in the SOUL trial (NCT03914326)